College of Medicine

Vencanna Announces Amended Definitive Agreement with The Cannavative Group, Completion of Name Change, Resumption of Trading and Operational Update

Retrieved on: 
Friday, February 23, 2024

Pursuant to the Amended Agreement, Vencanna will acquire all of the outstanding membership units of Cannavative through an all-share exchange.

Key Points: 
  • Pursuant to the Amended Agreement, Vencanna will acquire all of the outstanding membership units of Cannavative through an all-share exchange.
  • The exchangeable securities are exchangeable, at the option of the holder, on a one-for-one basis for equivalent securities of Vencanna.
  • On January 17, 2023, at an annual general and special meeting, the shareholders of Vencanna approved the name change.
  • The Company has engaged Independent Trading Group (ITG) Inc. to act as the broker through which the Bid will be conducted.

Nabla Appoints Clinical Leader Dr. Ed Lee as its Chief Medical Officer

Retrieved on: 
Thursday, February 8, 2024

Bringing 20 years of clinical and operational leadership experience, Dr. Lee will help drive Nabla's product vision and development

Key Points: 
  • Bringing 20 years of clinical and operational leadership experience, Dr. Lee will help drive Nabla's product vision and development
    BOSTON, Feb. 8, 2024 /PRNewswire/ -- Nabla , the leading ambient AI assistant for practitioners, today announced the appointment of Ed Lee, MD, MPH , as Chief Medical Officer.
  • He brings his expansive clinical expertise, executive experience, and Nabla Copilot implementation insights to the company to help refine and enhance the product and deployment strategy.
  • As Chief Medical Officer, Dr. Lee will be instrumental in shaping Copilot's clinical strategy and product roadmap, including RCM optimization, and he will provide feature refinement and enhancement recommendations to solidify Nabla as a leader in healthcare ambient AI.
  • He will also represent Nabla at the American Medical Informatics Association (AMIA), offering insights on the field of clinical informatics and contributing to AMIA policy responses.

Merck Manuals Details Key Facts to Know About Multiple Sclerosis

Retrieved on: 
Wednesday, February 7, 2024

The cause of MS is unknown, but some studies point to early exposure to certain viruses in triggering the immune system to attack the body's own tissue.

Key Points: 
  • The cause of MS is unknown, but some studies point to early exposure to certain viruses in triggering the immune system to attack the body's own tissue.
  • Individuals without a formal diagnosis may be tempted to ignore their illness, especially if symptoms have waned, says Levin.
  • But he adds it's crucial to work to uncover the cause of symptoms and discuss them with a healthcare professional.
  • Based on the condition and its symptoms, neurologists can guide patients toward the most effective treatments and medications.

Two New Board of Trustees Members Join Ultimate Medical Academy

Retrieved on: 
Tuesday, January 16, 2024

“Today we celebrate two new members of our board who have a proven track record of helping organizations reach new heights,” said UMA President Thomas Rametta.

Key Points: 
  • “Today we celebrate two new members of our board who have a proven track record of helping organizations reach new heights,” said UMA President Thomas Rametta.
  • “Their impressive backgrounds and experience will undoubtedly propel our learners forward in their education goals and careers in healthcare.”
    Jones and Collins are joining the now 11-member board of trustees.
  • Responsible for driving growth, Jones also leads new product innovation with a focus on developing customer facing technologies tackling supply chain disruptions.
  • The deep expertise and proven leadership that these new trustees bring to our board will help elevate our graduates to careers where they are needed most.

Amesite Inc. Partners with Central Michigan University to Launch a Pioneering Asynchronous Implicit Bias Course for Healthcare Professionals

Retrieved on: 
Thursday, January 4, 2024

Delivered through CMU’s Online Professional Education portal powered by Amesite's cutting-edge learning platform, this course is meticulously designed to deepen the understanding of implicit bias in healthcare settings.

Key Points: 
  • Delivered through CMU’s Online Professional Education portal powered by Amesite's cutting-edge learning platform, this course is meticulously designed to deepen the understanding of implicit bias in healthcare settings.
  • The asynchronous course equips healthcare professionals, educators and advocates with the knowledge and tools necessary to make a tangible difference in their respective fields.
  • Dr. Kaleb Patrick, Associate Vice President at Central Michigan University, expressed enthusiasm about this professional development course, stating, "This innovative course signifies our commitment to driving change in healthcare by tackling implicit bias.
  • The CMU course, hosted on the Amesite platform, is instrumental in creating a more equitable and just healthcare system."

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Retrieved on: 
Wednesday, December 13, 2023

“We are very pleased to continue advancing our ophthalmic gene therapy pipeline, which remains the Company’s primary focus.”

Key Points: 
  • “We are very pleased to continue advancing our ophthalmic gene therapy pipeline, which remains the Company’s primary focus.”
    This Phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic atrophy (GA) secondary to dAMD and will be conducted in two phases.
  • Phase 2 is a randomized expansion phase in which subjects will be randomized in a 1:1:1 ratio to either one of two OCU410 dose groups or to an untreated control group.
  • OCU410 is a potential curative therapy with a single sub-retinal injection that targets multiple pathways causing dAMD, including lipid metabolism, inflammation, oxidative stress, and complement activation.
  • Currently, the other therapeutic options available target only complement activation and require approximately 6-12 intravitreal injections annually.

UNIVERSITY OF SOUTH ALABAMA BREAKS GROUND ON $200 MILLION COLLEGE OF MEDICINE BUILDING

Retrieved on: 
Friday, December 8, 2023

MOBILE, Ala., Dec. 8, 2023 /PRNewswire/ -- The University of South Alabama broke ground Friday on a new 250,000 square foot Frederick P. Whiddon College of Medicine building that will allow the University to graduate more physicians and accelerate research and innovation. Alabama Gov. Kay Ivey and other supporters attended the event on South's campus.

Key Points: 
  • MOBILE, Ala., Dec. 8, 2023 /PRNewswire/ -- The University of South Alabama broke ground Friday on a new 250,000 square foot Frederick P. Whiddon College of Medicine building that will allow the University to graduate more physicians and accelerate research and innovation.
  • The new College of Medicine building will provide state-of-the-art laboratory spaces that will create flexibility and efficiency for research today and in the future.
  • The Whiddon College of Medicine at the University of South Alabama is one of 158 accredited MD-granting institutions in the United States, and one of only two in the state.
  • The USA Foundation contributed $30 million, while the State of Alabama has given $50 million in support of the project.

Baptist Health and FIU join forces to elevate care, address doctor shortage and boost medical research in South Florida

Retrieved on: 
Tuesday, November 28, 2023

Under the new enhanced affiliation with FIU, Baptist Hospital is on track to become a statutory teaching hospital with expanded undergraduate and graduate medical education programs, clinical research, and patient care.

Key Points: 
  • Under the new enhanced affiliation with FIU, Baptist Hospital is on track to become a statutory teaching hospital with expanded undergraduate and graduate medical education programs, clinical research, and patient care.
  • "This enhanced clinical and academic collaboration between Baptist Health and FIU's Herbert Wertheim College of Medicine will be transformative in reshaping healthcare in the region," said Baptist Health President and CEO Bo Boulenger.
  • "There is a great deal of excitement around this collaboration because it elevates the work both FIU and Baptist are doing," said FIU President Kenneth A. Jessell.
  • The two organizations have worked together for more than a decade to offer clinical rotations to medical students and an accredited medical residency program at Baptist Health West Kendall Baptist Hospital.

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Retrieved on: 
Monday, October 30, 2023

ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA.

Key Points: 
  • ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA.
  • A copy of the slides being presented will be available via the Company's investor website.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.
  • A replay of the webcast will also be available via the Company's investor website approximately two hours after the call's conclusion.

Independent Scientific Paper by Doctors Using IceCure's ProSense® Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patients

Retrieved on: 
Wednesday, October 25, 2023

CAESAREA, Israel, Oct. 25, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that a scientific paper titled "Cryoablation Therapy for Early-Stage Breast Cancer: Evidence and Rationale" was recently published in the Journal of Breast Imaging.

Key Points: 
  • Dr. Ward, a ProSense® user who specializes in women's imaging and breast tumor cryoablation, commented, "Combining breast imaging with minimally invasive procedures such as cryoablation with ProSense® is changing the paradigm of treatment for breast cancer.
  • We've seen excellent results in early-stage patients and the growing body of evidence published by practitioners around the world validates the results we are seeing first hand."
  • "We are grateful to the doctors who took the time and care to assess the literature, write, and publish this independent, non-sponsored scientific paper.
  • "Papers like this, combined with several independent studies of ProSense® cryoablation recently published, help to inform doctors and patients about how cryoablation can significantly improve patient outcomes and avoid aggressive treatment when it's not necessary,"